Table 2.
Baseline characteristics
| Parameter | Standard Algorithm n=30 | Simplified Algorithm n=21 | Total N=51 |
|---|---|---|---|
| Age, yr, mean (SD) | 53 (16) | 53 (16) | 53 (16) |
| Male sex, N (%) | 20 (67) | 12 (57) | 32 (63) |
| First kidney transplant, N (%) | 24 (80) | 16 (76) | 40 (78) |
| Living donor, N (%) | 15 (50) | 12 (57) | 27 (52.9) |
| Time since transplant, mo, median (IQR) | 95 (45–172) | 41 (19–99) | 77 (28–155) |
| Induction agent, N (%) | |||
| Antithymocyte globulin | 10 (33) | 3 (14) | 13 (26) |
| Antithymocyte globulin+basiliximab | 4 (13) | 5 (24) | 9 (18) |
| Basiliximab | 8 (27) | 12 (57) | 20 (39) |
| Unknown | 8 (27) | 1 (5) | 9 (18) |
| Baseline serum creatinine, mg/dl, mean (SD) | 1.53 (0.69) | 1.55 (0.77) | 1.54 (0.75) |
| Immunosuppressants, N (%) a | |||
| Tacrolimus | 24 (80) | 20 (95) | 44 (86) |
| Cyclosporine | 5 (17) | 1 (5) | 6 (12) |
| Sirolimus | 1 (3) | 1 (5) | 2 (4) |
| Mycophenolate | 22 (73) | 18 (85) | 40 (78) |
| Azathioprine | 2 (7) | 2 (10) | 4 (8) |
| COVID-19 vaccination status, N (%) | |||
| One dose | 0 | 1 (5) | 1 (2) |
| Two doses | 4 (13) | 0 | 4 (8) |
| Three doses | 12 (40) | 6 (3) | 18 (35) |
| Four doses | 14 (47) | 14 (67) | 28 (55) |
| Days between symptom onset and nirmatrelvir/ritonavir start, median (IQR) | 4 (2–4) | 2 (1–4) | 3 (2–4) |
| Interacting medications, N (%) | |||
| Calcium channel blockers | |||
| Amlodipine | 16 (53) | 11 (52) | 27 (53) |
| Diltiazem | 0 | 1 (5) | 1 (2) |
| Nifedipine | 0 | 3 (15) | 3 (6) |
| Statins | |||
| Rosuvastatin | 3 (10) | 1 (5) | 4 (8) |
| Atorvastatin | 18 (58) | 13 (62) | 31 (61) |
| Other | |||
| Tamsulosin | 2 (7) | 1 (5) | 3 (6) |
| Zopiclone | 1 (3) | 1 (5) | 2 (4) |
| Apixaban | 1 (3) | 1 (5) | 2 (4) |
| Colchicine | 1 (3) | 2 (10) | 3 (6) |
| No. of interacting comedications, median (range) | 2 (1–5) | 2 (1–4) | 2 (1–5) |
IQR, interquartile range; COVID-19, coronavirus disease 2019.
a
One patient was on both tacrolimus and sirolimus.